Featuring perspectives from Dr Richard Finn, Dr Lipika Goyal and Prof Arndt Vogel, moderated by Dr Katie Kelley. Published February 20, 2023. (Webinar Video Proceedings)
TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hepatobiliary cancers.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:
Richard S Finn, MD
Professor, Department of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California
Advisory Committee: CStone Pharmaceuticals; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, Lilly, Merck, Pfizer Inc; Contracted Research (to Institution): Adaptimmune, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Hengrui Therapeutics Inc; Speaker’s Bureau: Genentech, a member of the Roche Group.
Lipika Goyal, MD, MPhil
Director of Gastrointestinal Oncology
Stanford Cancer Center
Associate Professor
Stanford University School of Medicine
Palo Alto, California
Advisory Board and Consulting Agreements: Alentis Therapeutics AG, Black Diamond Therapeutics Inc, Exelixis Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Incyte Corporation, Kinnate Biopharma, Merck, QED Therapeutics, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Surface Oncology, Taiho Oncology Inc, TransThera Biosciences, Tyra Biosciences; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
Professor Arndt Vogel, MD
Managing Senior Consultant
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany
Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Böhringer Mannheim, Bristol-Myers Squibb Company, BTG, Daiichi Sankyo Inc, Eisai Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation; Speaker: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Böhringer Mannheim, Bristol-Myers Squibb Company, BTG, Daiichi Sankyo Inc, Eisai Inc, GlaxoSmithKline, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation.
MODERATOR
Robin K (Katie) Kelley, MD
Professor of Clinical Medicine, Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF)
San Francisco, California
Advisory Board: Kinnate Biopharma; Advisory Board or Steering Committee (to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Advisory Committee: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Kinnate Biopharma, Merck; Research Funding to Institution: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Relay Therapeutics, Surface Oncology, Taiho Oncology Inc; Uncompensated Service on IDMC: Genentech, a member of the Roche Group, Merck.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, and Merck.
Release date: February 2023
Expiration date: February 2024
(WIFI is recommended for best performance):